health
system
worldwid
grappl
pandem
patient
durabl
lvad
support
repres
uniqu
popul
risk
diseas
outlin
patient
develop
complic
cytokin
storm
sever
ard
myocardi
injuri
describ
challeng
aros
manag
patient
male
destin
therapi
heartmat
left
ventricular
assist
devic
lvad
implant
develop
fever
flank
pain
hematuria
three
day
attend
parti
evalu
nephrolithiasi
local
emerg
depart
ed
ct
abdomen
pelvi
incident
found
possibl
atyp
viral
pneumonia
test
coronaviru
diseas
left
medic
advic
ensu
day
continu
fever
new
onset
myalgia
diarrhea
dyspnea
return
ed
acut
hypox
respiratori
failur
requir
supplement
oxygen
maintain
peripher
oxygen
satur
medic
histori
includ
ischem
cardiomyopathi
stage
chronic
kidney
diseas
obes
postlvad
complic
includ
gastrointestin
bleed
ventricular
tachycardia
right
ventricular
rv
dysfunct
infecti
complic
diabet
tobacco
use
blood
group
posit
pretest
probabl
moder
high
due
fever
dyspnea
hypoxia
well
prior
imag
show
peripher
groundglass
opac
revers
transcript
polymeras
chain
reaction
rtpcr
sever
acut
respiratori
syndrom
coronaviru
posit
initi
ed
visit
institut
serial
laboratori
imag
test
detail
tabl
sever
marker
diseas
sever
abnorm
includ
absolut
lymphocyt
count
creactiv
protein
cardiac
enzym
chest
xray
show
bilater
infiltr
concern
atyp
pneumonia
figur
patient
quarantin
negativepressur
intens
care
room
figur
pandem
caus
novel
coronaviru
taken
stronghold
new
york
state
patient
heart
failur
lvad
support
uniqu
popul
risk
present
patient
develop
complic
cytokin
storm
sever
ard
myocardi
injuri
illustr
clinic
consider
aros
clinic
cours
host
respons
often
local
lung
parenchyma
surg
proinflammatori
cytokin
occur
known
cytokin
storm
phenomenon
describ
graftversushost
diseas
viral
ill
includ
influenza
complic
mod
includ
ard
cardiac
manifest
biomark
relat
cytokin
storm
includ
lymphopenia
creactiv
protein
lactat
dehydrogenas
ldh
ferritin
ddimer
troponin
siddiqi
mehra
propos
schema
assess
sever
system
hyperinflamm
guid
therapi
serial
evalu
inflammatori
marker
done
risk
stratifi
critic
ill
patient
milder
diseas
inflamm
myocardi
injuri
must
differenti
baselin
inflamm
often
encount
lvad
support
lvad
patient
sever
biomark
includ
ldh
absolut
lymphocyt
count
brain
natriuret
peptid
bnp
troponin
previous
obtain
lieu
absolut
valu
rel
chang
biomark
may
pertin
grade
sever
patient
lvad
support
patient
increas
inflammatori
cardiac
biomark
profil
baselin
worsen
diseas
progress
inflammatori
biomark
profil
improv
tocilizumab
chang
pattern
laboratori
marker
may
reliabl
tool
follow
lvad
patient
cardiac
manifest
experi
china
shown
could
advers
affect
cardiovascular
system
patient
evid
myocardi
injuri
part
present
myocardi
effect
like
multifactori
process
due
bystand
effect
mod
viral
myocard
activ
advers
remodel
mechan
furthermor
pea
arrest
patient
may
sequela
cardiac
damag
lvad
support
may
instrument
resuscit
context
manag
patient
lvad
support
difficult
complex
interplay
volum
statu
biventricular
dynam
close
monitor
rv
failur
need
inotrop
support
lvad
speed
drop
suction
event
low
flow
pulsatil
index
pi
event
due
vasoplegia
associ
infect
limit
healthcar
worker
hcw
exposur
nonessenti
test
echocardiogram
xray
ct
pulmonari
arteri
cathet
defer
physic
examin
jugular
venou
pressur
pulmonari
crackl
hepatojugular
reflux
essenti
make
clinic
decis
also
lvad
monitor
display
flow
paramet
mayb
use
surrog
cardiac
output
display
flow
correl
prior
invas
hemodynam
data
though
definit
therapi
multipl
ongo
random
trial
evalu
differ
treatment
antimalari
medic
hydroxychloroquin
chosen
initi
treatment
patient
shown
reduc
vitro
cell
entri
retrospect
studi
suggest
clinic
benefit
major
side
effect
qtc
prolong
protocol
provid
monitor
guidanc
complic
immunomodulatori
biolog
tocilizumab
reserv
sever
defin
presenc
worsen
respiratori
failur
cytokin
storm
evidenc
increas
inflammatori
marker
still
caution
warrant
major
advers
effect
tocilizumab
includ
infect
infus
reaction
dyslipidemia
neutropenia
potenti
malign
patient
lvad
support
particularli
vulner
infecti
complic
due
inher
presenc
hardwar
drivelin
exposur
well
fact
prolong
support
associ
immun
dysregul
final
prone
ventil
benefici
sever
ard
maneuv
effect
improv
lung
mechan
ga
exchang
case
may
prevent
need
escal
venousven
extracorpor
membran
oxygen
though
publish
outcom
earli
experi
wuhan
china
indic
prone
posit
wide
use
relat
sever
ard
possibl
benefit
nonetheless
may
prohibit
heart
failur
patient
lvad
support
prone
posit
could
result
complic
compress
outflow
graft
drivelin
impair
venou
return
increas
thorac
pressur
hardwar
malposit
worsen
rv
hemodynam
may
addit
anxieti
staff
care
patient
otherwis
familiar
lvad
manag
due
consider
prone
ventil
perform
patient
potenti
benefit
lvad
support
patient
ard
warrant
studi
inflammatori
profil
improv
tocilizumab
remain
critic
condit
maxim
ventilatori
support
vasopressor
shock
given
multipl
complic
earli
palli
care
discuss
initi
mod
continu
worsen
methylen
blue
administ
without
improv
hemodynam
patient
ultim
expir
hospit
day
case
highlight
systemat
approach
variou
consider
patient
lvad
develop
lifethreaten
manifest
